On Wednesday, Following U.S. Stocks were among the “Top Gainers”: Trinity Industries, (NYSE:TRN), NN, (NASDAQ:NNBR), Oncothyreon, (NASDAQ:ONTY), Halcón Resources Corporation, (NYSE:HK)
Trinity Industries, (NYSE:TRN), with shares inclined 6.65%, closed at $31.77.
NN, (NASDAQ:NNBR), with shares jumped 6.64%, settled at $21.04.
Oncothyreon, (NASDAQ:ONTY), with shares climbed 6.33%, and closed at $1.68.
Halcón Resources Corporation, (NYSE:HK), surged 6.29%, and closed at $1.69.
Latest NEWS regarding these Stocks are depicted underneath:
Trinity Industries Inc. (NYSE:TRN)
Formerly on March 5, Trinity Industries Inc. (TRN), has declared a quarterly dividend of 10 cents per share on its $1.00 par value ordinary stock. The quarterly cash dividend, representing Trinity’s 204th successively paid dividend, is payable April 30, 2015 to stockholders of record on April 15, 2015.
Trinity Industries, Inc. provides various products and services for the energy, transportation, chemical, and construction sectors in the United States and internationally.
NN Inc. (NASDAQ:NNBR)
NN Inc. (NNBR), a diversified industrial corporation, stated its financial results for the fourth quarter and twelve months ended December 31, 2014.
Fourth Quarter 2014 Results:
Net sales for the fourth quarter raised $63.7 million, or 71% to $153.8 million, as contrast to $90.1 million for the fourth quarter of 2013. This comprised of about $65.9 million in net sales from the four attainments. The influence of foreign exchange translation during the quarter was $2.0 million in sales resulting in an after tax influence of $0.2 million or $0.01 per diluted share for the quarter.
Adjusted revenue from operations which excludes attainment and other related expenses for the fourth quarter was $10.9 million, an raise of 68%, contrast to $6.5 million for the same period in 2013. Adjusted net revenue which excludes attainment and other related expenses raised to $5.7 million or $0.30 per diluted share, contrast to $4.5 million or $0.25 per diluted share for the same period in 2013. These raises can be attributed to the four attainments, in addition to improved operating performance within our legacy business.
Stated revenue from operations for the fourth quarter was $8.6 million which comprised of $2.3 million in attainment, integration and impairment charges, contrast to $6.5 million for the same period in 2013. Stated net revenue for the fourth quarter was $1.6 million or $0.08 per diluted share counting attainment, impairment and other non-recurring charges, contrast to $4.5 million or $0.25 per diluted share for the fourth quarter 2013.
NN, Inc. manufactures and sells metal bearing, plastic and rubber, and precision metal components for bearing, automotive, and industrial parts manufacturers worldwide.
Oncothyreon Inc (NASDAQ:ONTY)
Oncothyreon Inc (ONTY), stated financial results for the year and quarter ended December 31, 2014.
Net loss for the year ended December 31, 2014 was $50.0 million, or $0.64 per basic and diluted share, contrast with a net loss of $38.8 million, or $0.62 per basic and diluted share, for the comparable period in 2013. The rise in net loss was due to higher research and development expenses, primarily as a result of an raise of $10.0 million in license fees paid to Array. The raise in net loss was also the result of higher general and administrative expenses and lower non-cash revenue from the change in fair value of warrant liability, which was $0.8 million for the year ended December 31, 2014 contrast to $2.3 million for the year ended December 31, 2013.
Net loss for the three months ended December 31, 2014 was $27.6 million, or $0.30 per basic and diluted share, contrast with a net loss of $6.4 million, or $0.09 per basic and diluted share, for the comparable period in 2013. The rise in net loss for the three months ended December 31, 2014 contrast to the preceding year period was primarily attributable to an upfront payment of $20.0 million to Array in December 2014 and lower non-cash revenue from the change in the fair value of warrant liability, which was $0.3 million for the three months ended December 31, 2014 contrast to $1.2 million for the three months ended December 31, 2013.
As of December 31, 2014, Oncothyreon’s cash, cash equivalents and investments were $63.7 million, contrast to $72.6 million at December 31, 2013, a decrease of $8.9 million, or 12.3 percent. The decrease was primarily attributable to $48.4 million of cash used in operations during the year ended December 31, 2014, partially offset by the net proceeds of $40.2 million from the closing of concurrent but separate underwritten offerings of Oncothyreon ordinary stock and Series A convertible preferred stock in September 2014.
In February 2015, Oncothyreon closed additional concurrent but separate underwritten offerings of Oncothyreon ordinary stock and Series B convertible preferred stock, resulting in net proceeds of 22.4 million.
Oncothyreon Inc, a clinical-stage biopharmaceutical corporation, develops therapeutic products for the treatment of cancer. Its product candidate comprises Tecemotide, a vaccine for the treatment of non-small cell lung cancer.
Halcón Resources Corporation (NYSE:HK)
Formerly on February 25, Halcón Resources Corporation (HK), declared its fourth quarter and full year 2014 results.
Halcon generated total proceeds of $239.5 million for the quarter ended December 31, 2014. Proceeds for the full year 2014 totaled $1,148.3 million, an raise of 15% contrast to the full year 2013.
Production for the three months and full year ended December 31, 2014 was 46,076 barrels of oil equivalent per day (Boe/d) and 42,107 Boe/d, respectively. The Corporation stated full year 2014 production above its guidance range. Production was comprised of 81% oil, 9% natural gas liquids (NGLs) and 10% natural gas for the quarter and 83% oil, 7% NGLs and 10% natural gas for the year.
Counting the influence of hedges, Halcon realized 105% of the average NYMEX oil price, 35% of the average NYMEX oil price for NGLs and 94% of the average NYMEX natural gas price during the fourth quarter 2014. For the full year 2014, counting the influence of hedges, the Corporation realized 91% of the average NYMEX oil price, 36% of the average NYMEX oil price for NGLs and 94% of the average NYMEX natural gas price.
Total operating costs per unit, after adjusting for selected items, reduced by 23% to $21.27 per Boe during the three months ended December 31, 2014, contrast to the same period of 2013. Total operating costs per unit for the full year, after adjusting for selected items, were $24.14 per Boe, representing a decrease of 17% as compared to 2013.
After adjusting for selected items primarily related to the non-cash influence of derivatives and non-cash impairment charges (see Selected Item Review and Reconciliation table for additional information), net revenue was $20.6 million, or $0.05 per diluted share, and $71.7 million, or $0.17 per diluted share, for the quarter and full year ended December 31, 2014, respectively. Halcon stated net revenue accessible to ordinary stockholders of $247.3 million, or $0.48 per diluted share for the fourth quarter and $282.9 million, or $0.59 per diluted share for the year.
Halcón Resources Corporation, an independent energy corporation, is engaged in the attainment, production, exploration, and development of onshore oil and natural gas properties in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
